Publication date: Jul 01, 2024
Immunosuppressants, such as methotrexate (MTX), can suppress the COVID-19 vaccine response in patients with autoimmune diseases. Thus, this study aims to evaluate the effects of MTX hold following COVID-19 vaccination on vaccine efficacy response. A systematic review and meta-analysis of relevant studies retrieved from Web of Science, SCOPUS, PubMed, and CENTRAL from inception until Oct 1, 2023, was conducted. Covidence was used to screen the eligible articles, and all relevant outcomes data were synthesized using risk ratios (RRs) or standardized mean differences (SMDs) with 95% confidence intervals (CIs) in meta-analysis models within RevMan 5. 4. PROSPERO ID: CRD42024511628. Four studies with a total of 762 patients with autoimmune inflammatory disorders were included. Holding MTX following the COVID-19 vaccination for approximately 2 weeks was associated with significantly higher antibody titer (SMD: 0. 70, 95% CI [0. 54, 0. 87], P 10 or DAS28-CRP > 1. 2 either after 1st dose (RR: 2. 49 with 95% CI [1. 39, 4. 47], P = 0. 002) or 2nd dose (RR: 2. 16 with 95% CI [1. 37, 3. 41], P = 0. 0009) and self-reported disease flare (RR: 1. 71 with 95% CI [1. 35, 2. 17], P
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Methotrexate |
| disease | VO | COVID-19 vaccine |
| disease | MESH | autoimmune diseases |
| disease | MESH | COVID-19 |
| disease | VO | vaccination |
| disease | VO | vaccine efficacy |
| disease | VO | antibody titer |
| disease | VO | dose |
| disease | MESH | Long Covid |
| disease | VO | vaccine |